Latest Product Development News

Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.

Acrux Limited reports strong momentum from recent topical pharmaceutical launches, driving a significant uptick in profit share income expected in the coming quarter. The company also secured nearly $4 million through a placement and share purchase plan, alongside a $1.73 million R&D-backed loan.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Pointerra Limited’s Q3 FY25 results reveal delayed invoicing milestones pushed into Q4, yet strong progress across multiple sectors and promising product development underpin an optimistic cashflow outlook.

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

Appen Limited reported a 12% revenue increase excluding Google in Q1 FY25, alongside a significant improvement in underlying EBITDA and a robust cash position, setting a positive tone for the year ahead.

Li-S Energy Limited reported solid progress in its March 2025 quarter, advancing a key collaboration with Kea Aerospace to integrate lithium-sulfur batteries into high-altitude UAVs, while strengthening its board and maintaining a healthy cash position.

Ecofibre Limited reported a $2.2 million operating cash outflow in 3Q25 with total cash at $1.3 million, highlighting mixed progress across its business units and a pressing need to monetise assets to sustain operations.

Energy Action Ltd reported a robust 22.7% increase in revenue to $2.7 million for Q3 FY25, alongside positive operating cash flow and continued investment in its AI-driven Utilibox platform, signaling strong momentum in energy management innovation.

Energy Action Limited has posted a positive net operating cash flow of A$59,000 for the quarter ending March 31, 2025, while maintaining a robust cash balance of A$1.61 million. The company’s latest cash flow report reveals steady financing activity and prudent investment spending.

Bio-Gene Technology Limited has been awarded two significant grants totaling A$3 million by the US Department of Defense, validating its innovative insecticide technologies Flavocide® and Qcide®. The company is advancing regulatory filings and scaling production to target both military and civilian markets.